“Immediate challenges” for UK pharma post-Brexit, says ABPI
pharmafile | June 24, 2016 | News story | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | ABPI, brexit
The UK life sciences industry has expressed dismay at the result of the EU referendum, but has pledged to work with the government and other relevant bodies to ensure the long-term future of the UK pharmaceutical and biotech industries.
The Association of the British Pharmaceutical Industry says that the vote to leave the EU would create immediate problems that must be overcome, but indicated its willingness to take the appropriate steps.
CEO Mike Thompson comments: “The voice of the British people has been heard. This creates immediate challenges for future investment, research and jobs in our industry in the UK. With that being the case, we are committed to working closely with the government to agree what steps need to be taken to send a strong signal that the UK is open for business.”
The UK BioIndustry association expressed similar sentiments, while reiterating the UK’s strength in the life sciences field. CEO Steve Bates says: “This is not the outcome that the BIA wanted but we accept the views of the UK people. The life sciences sector is a resilient community, unfazed by new challenges and staffed by great management teams used to working in a global environment.
“Key questions about the regulation of medicine, access to the single market and talent, intellectual property and the precise nature of the future relationship of the UK with Europe are now upon is. This will require detailed and dispassionate thinking and the BIA will make its and its members’ expertise available to the government and its key agencies in the coming weeks and months as we work through these complex issues.”
Sean Murray
Related Content
New targeted lung cancer treatment coming to UK under MHRA scheme
The MHRA has issued an Early Access to Medicines Scheme (EAMS) positive scientific opinion for …
Sickle cell therapy granted innovation passport by MHRA
Bluebird bio has been granted an innovation passport, under the new UK approval process, for …
Biosimilars and Brexit: What’s in store for UK’s biosimilar market?
It’s been 15 years since the first biosimilar entered the market, and the impact of …
